Pharmaceutical

Shionogi secures licence for Maze’s Pompe disease treatment

Shionogi has concluded an exclusive global licence agreement for Maze Therapeutics’ MZE001 aimed at treating Pompe disease.

May 11, 2024 - 04:00
Shionogi secures licence for Maze’s Pompe disease treatment
Shionogi has concluded an exclusive global licence agreement for Maze Therapeutics’ MZE001 aimed at treating Pompe disease.
Read the original article

Tags:

Previous Article

Oral solid dosage manufacturing companies, equipment and market

Next Article

Formosa and Tabuk sign deal for FDA-approved ophthalmic suspension

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

ASCO 2024: Merus touts positive Phase II data for head and neck cancer antibody

ASCO 2024: Merus touts positive Phase II data for head ...

May 25, 2024

Why so few get screened for lung cancer, the deadliest cancer in the U.S.

Why so few get screened for lung cancer, the deadliest ...

Aug 19, 2023

Pre-diabetes rates increase amidst a renaissance for type 2 diabetes research

Pre-diabetes rates increase amidst a renaissance for ty...

Jun 16, 2024